A clinical trial to evaluate efficacy of topical netarsudil in comparison to topical latanoprost in primary angle closure disease spectrum

Efficacy and safety profile of Netarsudil 0.02% in in primary angle closure disease : A randomised comparative study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/02/049928

Enrollment

Registered

2023-02-21

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H402- Primary angle-closure glaucoma

Interventions

Intervention1: Netarsudil: one Group of patients will be subjected to Netarsudil 0.02% eye drop one drop topically once daily for Intraocular pressure control for 3 months Control Intervention1: Lata

Eligibility

Inclusion criteria

Inclusion criteria: Primary angle closure spectrum of patients with Intraocular more than 21 mmHg will be randomised to receive both the drugs.

Exclusion criteria

Exclusion criteria: one eyed patient, secondary glaucomas, open angle glaucoma, previous history of angle surgeries, previous history of trabecular meshwork lasers

Design outcomes

Primary

Measure	Time frame
Primary outcome: Percentage IOP reduction from baseline in both groups and its comparision at 3 monthsTimepoint: At end of 3 months the IOP reduction will be compared in form of percentage reduction	—

Secondary

Measure	Time frame
Best corrected visual acuity and visual field changes at 3 monthsTimepoint: 3rd month	—

Countries

India

Contacts

Public ContactDr Kshitij Donimath

Post graduate institute of medical education and research ,Chandigarh

dr.faisaltt@yahoo.com9914662345

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026